bluebird bio (BLUE) ASH Abstract Data Fairly Consistent With Previously Published Data - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
bluebird bio to Present New Data from Three LentiGlobinTM Clinical Studies at American Society of Hematology (ASH) Annual Meeting
November 3, 2016 9:01 AM EDTData from the Northstar (HGB-204) study of LentiGlobin drug product in transfusion-dependent -thalassemia (TDT) show that all five patients with non-0/0 genotypes and 12 months of follow-up remained free of transfusions, and patients with 0/0 genotypes and 12 months of follow-up (n=5) had a median reduction in transfusion volume of 60%
The median HbAT87Q level at six months in Northstar was 4.7 g/dl across all genotypes, and levels were generally sustained over the second year of follow-up
All patients with TDT from the HGB-205 study remained free of transfusions,... More
